AstraZeneca says Malaysia getting 6.4m Covid-19 vaccine shots at cost

AstraZeneca will supply 6.4 million doses of its Covid-19 vaccine to Malaysia next year without profit, according to the pharmaceutical firm’s country president.

Vaccine delivery

AstraZeneca Malaysia’s Dr Sanjeev Panchal also said the delivery of the AZD1222 vaccine would be within the first half of 2021.“We are proud to strengthen our commitment to Malaysia and support the government’s Covid-19 vaccine strategy. All by providing 6.4 million doses of the AstraZeneca/University of Oxford’s potential vaccine. AZD1222, at no profit during the amount of the pandemic.“I am grateful for the government’s guidance and leadership. Adding the appearance forward to deepening our cooperation to fight Covid-19,” he said during a statement today.

Dr Sanjeev also confirmed the supply agreement for the vaccine that Prime Minister Tan Sri Muhyiddin Yassin announced yesterday. In which would provide enough vaccination coverage for roughly 10 per cent of Malaysians.

The agreement

Under the agreement, AstraZeneca will expand its global manufacturing capacity to make sure a dedicated supply of AZD1222 for Malaysia.

This takes place in parallel to the ongoing clinical trials within the U.S., the UK, Brazil, South Africa, Japan and Russia.

An interim analysis of the phase III clinical trial programme conducted by Oxford with AZD1222, peer-reviewed and published in medical journal The Lancet on December 8, has indicated the vaccine is safe and effective at preventing symptomatic Covid-19 also as protecting against severe disease and hospitalization.

To this end, AstraZeneca is working along with the Health Ministry. Together with the Science, Technology and Innovation Ministry on the preparations for swift and science-led regulatory approval.

The vaccine uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus). That causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

More information about：

Content source: